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Introduction
Cancer immunotherapy in bladder superficial cancer evokes 
immune check points to invoke immunity to destroy cancer cells 
[1]. BCG binding to basement membrane fibronectin may be crucial in delayed type hypersensitivity and anti-tumor activity [2]. Intravesical BCG may induce infectious complications [3]. Although these infections may diagnosed with PPD- Enzyme 
linked immune spot assay after BCG vesical instillation [4].PPD hypersensitivity accompanied with longer survival however it may predict more serious complications [5]. PPD could not foretell the complications in all studies [6]. On the other hand some reported that PPD prior to intra vesical BCG may mend oncological outcome [7]. Moreover, serum BCG antibody elevation may correlate with immunoadjuvant response of intra vesical BCG thrapy [8]. Intra vesical BCG instillation is standard 
for superficial bladder cancer treatment [9]. More hypersensitive 
PPD skin test may forecast more side effects and less bladder tumor recurrence [10].
References
1. Saad FT, Hincal E, Kaymakamzade B (2017) Dynamics of immune 
checkpoints, immune system, and bcg in the treatment of superficial bladder cancer. Comput Math Methods Med 3573082: 1-9.
2. Ratliff TL (1989) Mechanisms of action of intravesical BCG for bladder cancer. Prog Clin Biol Res 310: 107-122.
3. Pérez Jacoiste Asín MA, Fernández Ruiz M, López Medrano F, Lumbreras 
C, Tejido A, et al. (2014) Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy 
for bladder cancer: incidence, risk factors, and outcome in a single-
institution series and review of the literature. Medicine (Baltimore) 
93(17): 236-254.
4. Heemstra KA, Bossink AW, Spermon R, Bouwman JJ, van der Kieft 
R, et al. (2012) Added value of use of purified protein derivative-
based enzyme-linked immunosorbent spot assay for patients with Mycobacterium bovis BCG infection after intravesical BCG instillations. 
Clin Vaccine Immunol 19(6): 974-977.
5. Bilen CY, Inci K, Erkan I, Ozen H (2003) The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin. J Urol 
169(5): 1702-1705.
6. Witjes JA, Fransen MP, van der Meijden AP, Doesburg WH, Debruyne 
FM (1993) Use of maintenance intravesical bacillus Calmette-Guérin 
(BCG), with or without intradermal BCG, in patients with recurrent 
superficial bladder cancer. Long-term follow-up of a randomized phase 
2 study. Urol Int 51(2): 67-72.
7. Niwa N, Kikuchi E, Matsumoto K, Kosaka T, Mizuno R, et al. (2018) 
Purified protein derivative skin test prior to bacillus Calmette-Guérin therapy may have therapeutic impact in patients with non-muscle-
invasive bladder cancer. J Urol pii: S0022-5347(18): 30006-30005.
8. Winters WD, Lamm DL (1981) Antibody responses to Bacillus Calmette-Guérin during immunotherapy in bladder cancer patients. 
Cancer Res 41(7): 2672-2676.
9.  Zheng YQ, Naguib YW, Dong Y, Shi YC, Bou S, et al. (2015) Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin 
Adv Biotech & Micro 9(2): AIBM.MS.ID.555759 (2018) 001
Abstract
Cancer immunotherapy in bladder superficial cancer evokes immune check points to invoke immunity to destroy cancer cells. PPD 
hypersensitivity accompanies with longer survival however it may predict more serious complications. More hypersensitive PPD skin test may forecast more side effects and less bladder tumor recurrence.
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